The Institute for Translational Neuroscience's greatest strength is bringing together different groups under one common goal: to advance neuroscience research at the University of Minnesota.
The Institute for Translational Neuroscience (ITN) was established in 2007 as a University-wide presidential initiative to promote the transfer of discoveries in the basic neurosciences to clinical practice. The institute is charged to enhance basic science discovery with new knowledge leading to subsequent clinical trials and establishment of new therapeutic principles or tools.
Our main goal is to attract and recruit top scientists to shape discoveries that will lead to tomorrow's cures. The institute exemplifies how different disciplines, departments, and centers can work together in partnership to evolve neurological disease research at the University of Minnesota. We have built a community that encourages learning, education, innovation, and discovery all of which are more successful in a team-oriented environment.
These world-class centers embrace and advance the institute's mission:
ITN in the News - ITN Scholar Keith Vossel Research Highlight
ITN Scholar Keith Vossel, MD, was featured on the University of Minnesota's news page. Vossel is researching the role that silent seizures play in Alzheimer's disease. With colleagues at the University of California San Francisco (UCSF), Vossel found previously undetected electrical activity similar to epileptic seizures in 42 percent of Alzheimer’s disease patients—four times the incidence in matched controls. The U of M is now sponsoring a phase II clinical trial of one FDA-approved antiseizure drug to treat the epileptic activity associated with Alzheimer’s disease. Begun at UCSF, the trial started enrolling patients at the U of M last fall—shortly after Vossel, formerly of UCSF, arrived here. The trial is expected to conclude in early 2020.